DTaP vaccines from north american vaccine (NAVA): composition and critical parameters.
NAVA's acellular pertussis vaccine is based on highly purified pertussis toxin (PT) inactivated with H(2)O(2). PT was analysed using advanced biochemical methodology including mass spectroscopy (LC/MS), yielding mass and peptide mapping information on the subunits. Pertactin, adenylate cyclase, and Fim 1, 2 were below detection levels and only trace amounts of filamentous haemagglutinin (FHA) have been identified as a minor impurity. The vaccine does not induce anti-FHA antibodies during the course of a 3-dose primary immunization series in infants. B and T cell epitopes are preserved to a higher extent after H(2)O(2)detoxification when compared with chemical inactivation with formaldehyde, thus providing new information explaining why vaccines employing formaldehyde detoxified PT may need additional pertussis components added to induce high levels of protection. Anti-PT antibodies generated by NAVA diphtheria, tetanus, and acellular pertussis vaccine (DTaP) showed a positive correlation with protection against WHO-defined pertussis. The safety profiles for these vaccines showed low reactogenicity with no serious adverse events due to the vaccines.
Heron
I
I
North American Vaccine Inc., Columbia, MD, USA.
Chen
F M
FM
Fusco
J
J
D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000737:chemistry* / Q000592:standards; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007115:Immunization Schedule; D007223:Infant
D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines